Abstract
Pleiotropic drug resistance (PDR) is a well-described phenomenon occurring in fungi. PDR shares several similarities with processes in bacteria and higher eukaryotes. In mammalian cells, multidrug resistance (MDR) develops from an initial single drug resistance, eventually leading to a broad cross-resistance to many structurally and functionally unrelated compounds. Notably, a number of membrane-embedded energy-consuming ATP-binding cassette (ABC) transporters have been implicated in the development of PDR/MDR phenotypes. The yeast Saccharomyces cerevisiae genome harbors some 30 genes encoding ABC proteins, several of which mediate PDR. Therefore, yeast served as an important model organism to study the functions of evolutionary conserved ABC genes, including those mediating clinical antifungal resistance in fungal pathogens. Moreover, yeast cells lacking endogenous ABC pumps are hypersensitive to many antifungal drugs, making them suitable for functional studies and cloning of ABC transporters from fungal pathogens such as Candida albicans. This review discusses drug resistance phenomena mediated by ABC transporters in the model system S. cerevisiae and certain fungal pathogens.
Keywords: Fungal ABC transporters, PDR network, drug resistance, stress, regulation
Current Drug Targets
Title: Fungal ATP-Binding Cassette (ABC) Transporters in Drug Resistance & Detoxification
Volume: 7 Issue: 4
Author(s): Gyorgy Sipos and Karl Kuchler
Affiliation:
Keywords: Fungal ABC transporters, PDR network, drug resistance, stress, regulation
Abstract: Pleiotropic drug resistance (PDR) is a well-described phenomenon occurring in fungi. PDR shares several similarities with processes in bacteria and higher eukaryotes. In mammalian cells, multidrug resistance (MDR) develops from an initial single drug resistance, eventually leading to a broad cross-resistance to many structurally and functionally unrelated compounds. Notably, a number of membrane-embedded energy-consuming ATP-binding cassette (ABC) transporters have been implicated in the development of PDR/MDR phenotypes. The yeast Saccharomyces cerevisiae genome harbors some 30 genes encoding ABC proteins, several of which mediate PDR. Therefore, yeast served as an important model organism to study the functions of evolutionary conserved ABC genes, including those mediating clinical antifungal resistance in fungal pathogens. Moreover, yeast cells lacking endogenous ABC pumps are hypersensitive to many antifungal drugs, making them suitable for functional studies and cloning of ABC transporters from fungal pathogens such as Candida albicans. This review discusses drug resistance phenomena mediated by ABC transporters in the model system S. cerevisiae and certain fungal pathogens.
Export Options
About this article
Cite this article as:
Sipos Gyorgy and Kuchler Karl, Fungal ATP-Binding Cassette (ABC) Transporters in Drug Resistance & Detoxification, Current Drug Targets 2006; 7 (4) . https://dx.doi.org/10.2174/138945006776359403
DOI https://dx.doi.org/10.2174/138945006776359403 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Death Receptor Signaling in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Mitochondrial Pathology in Osteoarthritic Chondrocytes
Current Drug Targets The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Current Pharmaceutical Design Transient Receptor Potential (TRP) Cation Channels in Diabetes
Current Topics in Medicinal Chemistry HIV-1 Cell-to-Cell Transmission and Antiviral Strategies: An Overview
Current Drug Targets Anti-Inflammatory Effects of Fibrates: An Overview
Current Medicinal Chemistry Integrins: Novel Therapeutic Targets for Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Protease-Activated Receptor-2 Antagonists and Agonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine The Chick Embryo Chorioallantoic Membrane Model: A Research Approach for <i>Ex Vivo</i> and <i>In Vivo</i> Experiments
Current Medicinal Chemistry Current Therapeutic Options for Alzheimers Disease
Current Genomics Reconstructing the Hsp90/Tau Machine
Current Enzyme Inhibition Tamarind Inhibits Solar-Simulated Ultraviolet Radiation-Induced Suppression of Recall Responses in Humans
Letters in Drug Design & Discovery Selenium: A Cure for Autoimmune Thyroiditis
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Manipulation of the Immune System: Enhancement of Innate and Adaptive Mucosal Immunity
Current Pharmaceutical Design A Needle-Free Approach for Topical Immunization: Antigen Delivery via Vesicular Carrier System(s)
Current Medicinal Chemistry Intracellular Signaling Pathways Regulating Pluripotency of Embryonic Stem Cells
Current Stem Cell Research & Therapy Metformin, A New Era for an Old Drug in the Treatment of Immune Mediated Disease?
Current Drug Targets Genetically-modified Stem Cell in Regenerative Medicine and Cancer Therapy; A New Era
Current Gene Therapy